Abstract: Objective 　To analyze the relationship between expression of ERCC21 (excisition repair cross complement21) 、survivin and sensitivity and prognosis of cisplatin2contained regimens first2line chemo2 therapy in advanced lung adenocarcinoma. Methods 　IHC was used to evaluate expression of ERCC21 and survivin in 80 pathologically confirmed advanced lung adenocarcinoma patient s given cisplatin2contained regimens first2line chemotherapy. The response rate and survival time were analyzed according to the ex2 pression of ERCC21 and survivin. Results 　Only 77 patient s could be reviewed by IHC staining. The ex2 pression rates of ERCC21 and survivin were 33. 77 % and 53. 25 % respectively. The worse response rate and shorter TTP/ PFS could be identified in ERCC21 positive group. Patient s with positive expression of survivin had worse survival time. Con2 clusion 　Expression of ERCC21 may be a molecular marker of cisplatin2con2 tained regimens first2line chemothera2 py resistance and poor prognosis in ad2 vanced lung adenocarcinoma patient s.Simiary expression of survivin predicates poor prognosis for patient s with advanced lung adenocarcinoma.